Related Experiment Video
Updated: Jan 10, 2026

Myocardial Infarction by Percutaneous Embolization Coil Deployment in a Swine Model
Published on: November 4, 2021
Splenic Artery Aneurysm Associated with Myelofibrosis Managed by Coil Embolization
Itaru Watanabe1, Tatsuya Konishi1,2, Jun Yamanouchi1,2
1Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Japan.
Abstract:
Myelofibrosis (MF) is a myeloproliferative neoplasm frequently complicated by splenomegaly, with vascular abnormalities, such as splenic artery aneurysm (SAA), rarely reported. We herein report a 74-year-old woman with secondary MF harboring a JAK2 V617F mutation who developed SAA requiring intervention because of its potential risk of rupture. Ruxolitinib therapy markedly reduced splenomegaly and improved constitutional symptoms, thereby optimizing hemodynamic conditions and overall status for safe spleen-preserving coil embolization. This case highlights the potential relationship between MF and aneurysm formation while demonstrating that concomitant Janus kinase inhibitor therapy may facilitate safe endovascular treatment in select patients.
Insights
Myelofibrosis can lead to splenic artery aneurysms. JAK inhibitor therapy helped manage spleen size, enabling safe treatment for this rare vascular complication.
Area of Science:
- Hematology
- Vascular Surgery
- Oncology
Background:
- Myelofibrosis (MF) is a myeloproliferative neoplasm often associated with splenomegaly.
- Splenic artery aneurysms (SAA) are rare vascular complications in MF patients.
- The JAK2 V617F mutation is common in secondary MF.
Purpose of the Study:
- To report a case of secondary MF with SAA.
- To illustrate the management of SAA in an MF patient.
- To explore the role of JAK inhibitor therapy in facilitating endovascular treatment.
Main Methods:
- Case report of a 74-year-old woman with secondary MF and SAA.
- Treatment with Ruxolitinib to reduce splenomegaly and constitutional symptoms.
- Spleen-preserving coil embolization for SAA intervention.
Main Results:
- Ruxolitinib therapy effectively reduced splenomegaly and improved symptoms.
- The patient's condition was optimized for safe coil embolization.
- Successful spleen-preserving endovascular treatment of SAA was achieved.
Conclusions:
- MF may be associated with aneurysm formation.
- JAK inhibitor therapy can optimize patients for safe endovascular procedures.
- This case highlights a potential management strategy for SAA in MF patients.
Related Concept Videos
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Aneurysm III: Interprofessional Care
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
Venous Thrombosis III: Interprofessional Care

